WFH Humanitarian Aid Program
The lack of access to care and treatment in developing countries is an urgent and important public health challenge, as the cost of products to treat is prohibitively expensive for the majority of those affected with a bleeding disorder.
The WFH is leading the effort to change this lack of access in emerging countries by providing consistent and predictable access to Treatment for All.
1996-2019:
0
2020:
0
TREATMENT FOR ALL
The lack of access to care and treatment in emerging countries is an urgent and important public health challenge.
The WFH is leading the effort to change this lack of access by providing consistent and predictable treatment for all people with inherited bleeding disorders.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in emerging countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda.
CONTRIBUTORS
Founding Visionary
Sanofi/Sobi
Visionary
Bayer
Roche
Leadership
Grifols
Contributors
CSL Behring
Takeda
WFH Humanitarian Aid Program: Impact Report 2020
The lack of access to care, clotting factor concentrates and treatment for people affected by a bleeding disorder in developing countries is an urgent and important public health challenge. This daily challenge was magnified in 2020 due to the COVID-19 pandemic.
The WFH Humanitarian Aid Program was developed to address the issue of access to care by working with WFH NMOs to provide continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and prophylaxis for young children. In 2020, the program quickly responded to the COVID-19 pandemic by bringing education online and by collaborating with local organizations facing logistical restrictions in order to ensure that care would not be interrupted. 2020 also saw the WFH deliver the very first shipments of emicizumab to patients—a new prophylactic treatment to reduce the frequency of bleeding episodes in adults and children of all ages, newborn and older, with hemophilia A, with and without factor VIII inhibitors.
WFH Humanitarian Aid Program: Impact Report 2019
WFH Humanitarian Aid Program: Impact Report 2018